161 related articles for article (PubMed ID: 37545217)
21. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
[TBL] [Abstract][Full Text] [Related]
22.
Bang H; Lee MS; Sung M; Choi J; An S; Kim SH; Lee SE; Choi YL
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741260
[TBL] [Abstract][Full Text] [Related]
23. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
[TBL] [Abstract][Full Text] [Related]
25. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
[TBL] [Abstract][Full Text] [Related]
26. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
Sholl LM; Zheng M; Nardi V; Hornick JL
Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
[TBL] [Abstract][Full Text] [Related]
27. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
[TBL] [Abstract][Full Text] [Related]
28. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
Hum Pathol; 2024 Apr; ():. PubMed ID: 38653403
[TBL] [Abstract][Full Text] [Related]
31. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
Wu S; Liu Y; Shi X; Zhou W; Zeng X
Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
[TBL] [Abstract][Full Text] [Related]
32. A rare case of recurrent ovarian cancer with
Endo Y; Watanabe T; Saito M; Saito K; Suzuki R; Sano H; Natori Y; Sasaki E; Ueda M; Kamo N; Furukawa S; Soeda S; Kono K; Saji S; Fujimori K
Mol Clin Oncol; 2022 Apr; 16(4):90. PubMed ID: 35251641
[No Abstract] [Full Text] [Related]
33. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples.
Bourhis A; Redoulez G; Quintin-Roué I; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):194-196. PubMed ID: 30920961
[TBL] [Abstract][Full Text] [Related]
34. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F
Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803
[TBL] [Abstract][Full Text] [Related]
35. GISTs with
Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
[TBL] [Abstract][Full Text] [Related]
37. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
38. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
Hyrcza MD; Martins-Filho SN; Spatz A; Wang HJ; Purgina BM; Desmeules P; Park PC; Bigras G; Jung S; Cutz JC; Xu Z; Berman DM; Sheffield BS; Cheung CC; Leduc C; Hwang DM; Ionescu D; Klonowski P; Chevarie-Davis M; Chami R; Lo B; Stockley TL; Tsao MS; Torlakovic E
Mod Pathol; 2024 Jan; 37(1):100384. PubMed ID: 37972928
[TBL] [Abstract][Full Text] [Related]
39. NTRK Fusion in a Cohort of BRAF p. V600E Wild-Type Papillary Thyroid Carcinomas.
Lee SE; Lee MS; Bang H; Kim MY; Choi YL; Oh YL
Mod Pathol; 2023 Aug; 36(8):100180. PubMed ID: 37003481
[TBL] [Abstract][Full Text] [Related]
40.
Overbeck TR; Reiffert A; Schmitz K; Rittmeyer A; Körber W; Hugo S; Schnalke J; Lukat L; Hugo T; Hinterthaner M; Reuter-Jessen K; Schildhaus HU
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
